SecBot SecBot

BCRX

BIOCRYST PHARMACEUTICALS INC
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0000882796 Biotech & Drug Discovery
$7.45 −0.16 (−2.10%)
Nov 16 4:00 PM ET · prev $7.61
Market cap
$2.0B
Small cap
Consensus
Buy
82% Buy or better · 17 analysts
Median target
$17.00
+128% · range $11.00–32.00
1 year
+6.0%
from $7.03 · Nov 17
30 days
−7.7%
from $8.07
52-week range
$6.24–11.11
−33% from high · low Feb 5
Avg volume 20D
5.49M
Nov 5 spike 15.36M
Short interest
27.64M
≈10.7% of shares · +3.9%
Days to cover
5.1
at average volume
Insider net
−$2.6M
0 buyers · 3 sellers · 12 mo
New fund stakes
1
Q3 2026 13F · 2 exits
Filing reports
18
analyzed by SecBot
SecBot read BULLISH 8 reports · 90 days
Balance 0 bearish · 2 bullish · 1 mixed · 5 neutral oldest → newest, height = score
Avg score ·High conf. 5/8

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    3 insiders sold $2.6M.

  • InstitutionsMIXED

    Q3 2026: 36 added (1 new), 32 trimmed or exited. Largest new: Arrowstreet Capital, Limited Partnership $12.7M.

  • AnalystsBULLISH

    14 of 17 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate $0.125 → $0.100 over 90 days. 0 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest +3.9% to 27.64M shares. 5.1 days to cover, ≈10.7% of shares.

  • TrendDOWNTREND

    9% below its 50-day average.

Who's buying

13F· Q3 2026
1
new positions
2
exits
$12.7M
in new stakes
FundMoveSharesValue
JUPITER ASSET MANAGEMENT LTDDOUBLED3,996,048$33.3M
MORGAN STANLEYADD3,450,301$28.7M
HRT FINANCIAL LPDOUBLED2,698,999$22.5M
JPMORGAN CHASE & CODOUBLED2,040,228$17.0M
Invesco Ltd.ADD1,604,864$13.4M
ARROWSTREET CAPITAL, LIMITED PARTNERSHIPNEW1,521,753$12.7M
DIMENSIONAL FUND ADVISORS LPTRIM1,361,884$11.3M
IMC-Chicago, LLCTRIM1,145,722$9.5M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

17 analysts
Buy 82% rate it Buy or better
Strong Buy5Buy9Hold3Sell0Strong Sell0
12-month targets · 11 analysts

Price is below the lowest target. Median implies +128%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 5, 2026Wedbush
MAINTAIN
MAINTAINOutperform
Oct 19, 2026Wedbush
MAINTAIN
MAINTAINOutperform
Sep 30, 2026JP Morgan
MAINTAIN
MAINTAINNeutral
Sep 10, 2026RBC Capital
DOWNGRADE
DOWNGRADESector Perform
Sep 8, 2026Needham
REITERATE
REITERATEBuy
Aug 6, 2026RBC Capital
MAINTAIN
MAINTAINOutperform

Insider ledger

Form 4
$0
bought · 0 insiders
$2.6M
sold · 3 insiders
DateInsiderTypeValue
Aug 31, 2026
McKee Amy E
Director
Aug 31, 2026
AWARD$6.2K
Aug 31, 2026
Milne Jill C.
Director
Aug 31, 2026
AWARD$12.5K
Aug 31, 2026
Stonehouse Jon P
Director
Aug 31, 2026
AWARD$6.2K
Aug 31, 2026
Frank Steven
Director
Aug 31, 2026
AWARD$12.5K
Aug 31, 2026
MILANO VINCENT
Director
Aug 31, 2026
AWARD$11.2K
Jun 11, 2026
Frank Steven
Director
Jun 11, 2026
AWARD15,294 sh
Jun 11, 2026
Frank Steven
Director
Jun 11, 2026
AWARD33,540 sh
Jun 11, 2026
LEVIN ALAN G
Director
Jun 11, 2026
AWARD15,294 sh

Earnings setup

Estimates
$0.10
EPS estimate, this quarter
−20%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q$0.10$0.09–$0.11-20.0%$165.8M
Next Q$0.17$0.17–$0.18+16.7%$166.9M
Current FY$0.86$0.85–$0.88+16.1%$718.4M
Next FY🔒 Fresh data, subscribers only
Congressional trades
BCRX trades disclosed by members of Congress, with disclosure delay.
1 members · 1 buys / 0 sells
DateMemberType AmountDisclosed
Jul 10, 2026 Gilbert CisnerosDHouse BioCryst Pharmaceuticals Inc BUY $1K–$15K Sep 4, 2026 +56d

Short side

FINRA· Oct 30, 2026
27,637,852
shares short
+3.9%
vs prior settlement
5.1
days to cover
≈10.7%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 13, 2026 Press
BioCryst presented two real-world studies at ACAAI 2026 showing that ORLADEYO (berotralstat) reduces hospitalizations…
Impact 3/10
Nov 13, 2026 FDA
BioCryst Presents New Real-World Evidence Showing Reduced Angioedema-Related Medical Visits After Switching to ORLADEYO® (berotralstat) at ACAAI 2026 Annual Scientific Meeting
Two real-world studies demonstrate reductions in healthcare resource utilization in HAE patients who
Nov 10, 2026 SEC
State Street Corporation filed a Schedule 13G disclosing a passive 4.8% stake in BioCryst Pharmaceuticals as of…
SC 13G · Impact 3/10
Nov 4, 2026 SEC
BioCryst reported Q3 2026 total revenue of $180.3M (+13% YoY) and ORLADEYO revenue of $174.8M (+10% YoY), with GAAP…
8-K · Impact 6/10
Sep 30, 2026 Inst.
JUPITER ASSET MANAGEMENT LTD · DOUBLED
3,996,048 shares ($33.3M)
Sep 30, 2026 Inst.
MORGAN STANLEY · ADD
3,450,301 shares ($28.7M)
Aug 31, 2026 Insider
McKee Amy E was granted 644 shares
Director @ $9.70 ($6.2K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
3 drugs tracked · Drug pipeline →
Recent

SecBot reports

18 filings · 2 press releases · 5 bullish · 0 bearish · 1 mixed · 12 neutral
All BCRX filing & press-release reports (20)